Bjørn Kantsø1, Jacob Simonsen2, Steen Hoffmann3, Palle Valentiner-Branth4, Andreas Munk Petersen5,6, Tine Jess2,7. 1. Department of Microbiological Diagnostics and Virology, Statens Serum Institut, Copenhagen, Denmark. 2. Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. 3. Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark. 4. Department of Infectious Disease Epidemiology, Statens Serum Institut, Copenhagen, Denmark. 5. Department of Gastroenterology, Hvidovre University Hospital, Hvidovre, Denmark. 6. Department of Clinical Microbiology, Hvidovre University Hospital, Hvidovre, Denmark. 7. Department of Clinical Epidemiology, University of Aalborg, Aalborg, Denmark.
Abstract
OBJECTIVES: Inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC) are chronic diseases characterized by an inappropriate immune response, which may also increase the risk of infections. We investigated the risk of invasive pneumococcal disease (IPD) before and after diagnosis of IBD in a population-based cohort study. METHODS: In a cohort of 74,156 IBD patients and 1,482,363 non-IBD controls included and followed during 1977-2013, hazard rate ratios (HRs) for IPD in IBD patients vs. controls were calculated by Cox regression. Within the IBD group, we also calculated the risk according to ever use of specific IBD medications. Next, using conditional logistic regression, we evaluated the odds of IPD prior to IBD diagnosis. RESULTS: The HRs for IPD within the first 6 months after IBD diagnosis were significantly and more than threefold increased and then decreased to a constant level, which for CD was significantly increased (approximately twofold, HR, 1.99; 95% confidence interval (CI), 1.59-2.49) and for UC non-significantly just above 1. IBD medication use including tumor necrosis factor alpha antagonists had limited impact on the risk of IPD, although having ever used azathioprine increased the risk of IPD in patients with UC (HR, 2.38; 95% CI, 1.00-5.67). Up to 4 years prior to IBD diagnosis, the odds ratio for IPD was significantly increased (UC HR, 1.51, 95% CI, 1.05-2.17; CD HR, 1.79, 95% CI, 1.05-3.03). CONCLUSIONS: The risk of IPD is significantly increased both before and after diagnosis of IBD, with limited impact of IBD medications. This suggests that the risk of IPD in patients with IBD is related to the underlying altered immune response in these patients.
OBJECTIVES:Inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC) are chronic diseases characterized by an inappropriate immune response, which may also increase the risk of infections. We investigated the risk of invasive pneumococcal disease (IPD) before and after diagnosis of IBD in a population-based cohort study. METHODS: In a cohort of 74,156 IBD patients and 1,482,363 non-IBD controls included and followed during 1977-2013, hazard rate ratios (HRs) for IPD in IBD patients vs. controls were calculated by Cox regression. Within the IBD group, we also calculated the risk according to ever use of specific IBD medications. Next, using conditional logistic regression, we evaluated the odds of IPD prior to IBD diagnosis. RESULTS: The HRs for IPD within the first 6 months after IBD diagnosis were significantly and more than threefold increased and then decreased to a constant level, which for CD was significantly increased (approximately twofold, HR, 1.99; 95% confidence interval (CI), 1.59-2.49) and for UC non-significantly just above 1. IBD medication use including tumor necrosis factor alpha antagonists had limited impact on the risk of IPD, although having ever used azathioprine increased the risk of IPD in patients with UC (HR, 2.38; 95% CI, 1.00-5.67). Up to 4 years prior to IBD diagnosis, the odds ratio for IPD was significantly increased (UC HR, 1.51, 95% CI, 1.05-2.17; CD HR, 1.79, 95% CI, 1.05-3.03). CONCLUSIONS: The risk of IPD is significantly increased both before and after diagnosis of IBD, with limited impact of IBD medications. This suggests that the risk of IPD in patients with IBD is related to the underlying altered immune response in these patients.
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori Journal: JAMA Date: 2006-05-17 Impact factor: 56.272
Authors: Anja E Schauer; Tilman E Klassert; Carolin von Lachner; Diana Riebold; Anne Schneeweiß; Magdalena Stock; Mario M Müller; Sven Hammerschmidt; Philip Bufler; Ulrike Seifert; Kristina Dietert; Charles A Dinarello; Marcel F Nold; Achim D Gruber; Claudia A Nold-Petry; Hortense Slevogt Journal: J Innate Immun Date: 2017-06-10 Impact factor: 7.349
Authors: Christine N Manser; Michel H Maillard; Gerhard Rogler; Philipp Schreiner; Florian Rieder; Silja Bühler Journal: Digestion Date: 2020-01-22 Impact factor: 3.216
Authors: Martin H Gregory; Matthew A Ciorba; Wyndy L Wiitala; Ryan W Stidham; Peter Higgins; S Celeste Morley; Jason K Hou; Linda A Feagins; Shail M Govani; Shirley A Cohen-Mekelburg; Akbar K Waljee Journal: Inflamm Bowel Dis Date: 2020-05-12 Impact factor: 5.325